+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Multiple Sclerosis: Epidemiology Forecast to 2028

  • PDF Icon

    Report

  • 38 Pages
  • November 2019
  • Region: Global
  • GlobalData
  • ID: 4894984
Multiple Sclerosis: Epidemiology Forecast to 2028

Summary

Multiple sclerosis (MS) is an autoimmune disease affecting principally the central nervous system that causes nerve sheath demyelination followed by axon damage and paralysis. MS symptoms include muscle weakness, weak reflexes, tremors, muscle spasm, prolonged double vision, slurred speech, and balance problems. MS can occur at any age, but commonly affects people of ages 15-60 years. The diagnosis of MS depends upon patients’ symptoms, magnetic resonance imaging (MRI), and laboratory results, but it is mostly diagnosed in the late phases. Presently, MS is diagnosed by the widely used McDonald criteria, which is a combination of laboratory, clinical, and radiology reports of lesions at different times in different body areas.

The epidemiologists utilized county-specific studies published in peer-reviewed journals as well as medical record review studies to build the forecast. The disease definition for MS was consistent as per the McDonald criteria. The report includes a 10-year epidemiological forecast for the diagnosed incident and diagnosed prevalent cases of MS in the 7MM.

The following data describes epidemiology of MS. The epidemiologists forecast an increase in the diagnosed incident cases of MS in the 7MM from 53,299 cases in 2018 to 54,218 cases by 2028, at an AGR of 0.17% during the forecast period. The diagnosed prevalent cases of MS in the 7MM are expected to increase from 1,445,209 cases in 2018 to 1,595,707 cases by 2028, at an AGR of 1.04%. MS is more common in women than men and is more common in young adults. These trends are reflected in the forecast for the diagnosed incident cases, and diagnosed prevalent cases for the 7MM.

Scope

  • The Multiple Sclerosis (MS) Epidemiology Report provides an overview of the risk factors and global trends of MS in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
  • The report includes a 10-year epidemiological forecast for the diagnosed incident cases and diagnosed prevalent cases of MS segmented by sex, and age (all ages) in these markets. The diagnosed prevalent cases of MS are further segmented by type (relapsing-remitting [RRMS], primary progressive [PPMS], and secondary progressive [SPMS])
  • The multiple sclerosis epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The Multiple Sclerosis Epidemiology series will allow you to -
  • Develop business strategies by understanding the trends shaping and driving the global multiple sclerosis market.
  • Quantify patient populations in the global multiple sclerosis market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for multiple sclerosis therapeutics in each of the markets covered.
  • Understand magnitude of multiple sclerosis population by severity at diagnosis.

Table of Contents

1 Multiple Sclerosis: Executive Summary
1.1 Related Reports
1.2 Upcoming Reports
2 Epidemiology
2.1 Disease Background
2.2 Risk Factors and Comorbidities
2.3 Global and Historical Trends
2.4 Forecast Methodology
2.4.1 Sources
2.4.2 Forecast Assumptions and Methods
2.5 Epidemiological Forecast for MS (2018-2028)
2.5.1 Diagnosed Incident Cases of MS
2.5.2 Age-Specific Diagnosed Incident Cases of MS
2.5.3 Sex-Specific Diagnosed Incident Cases of MS
2.5.4 Diagnosed Prevalent Cases of MS
2.5.5 Age-Specific Diagnosed Prevalent Cases of MS
2.5.6 Sex-Specific Diagnosed Prevalent Cases of MS
2.5.7 Diagnosed Prevalent Cases of MS by Type
2.6 Discussion
2.6.1 Epidemiological Forecast Insight
2.6.2 Limitations of Analysis
2.6.3 Strengths of Analysis
3 Appendix
List of Tables
Table 1: Risk Factors and Comorbid Conditions Associated with MS
List of Figures
Figure 1: 7MM, Diagnosed Incident Cases of MS, N, Both Sexes, All Ages, 2018 and 2028
Figure 2: 7MM, Diagnosed Prevalent Cases of MS, N, Both Sexes, All Ages, 2018 and 2028
Figure 3: 7MM, Diagnosed Incidence of MS (Cases per 100,000 Population), Men and Women, All Ages, 2018
Figure 4: 7MM, Diagnosed Prevalence of MS (%), Men and Women, All Ages, 2018
Figure 5: 7MM, Sources Used and Not Used to Forecast the Diagnosed Incident Cases of MS
Figure 6: 7MM, Sources Used and Not Used to Forecast the Diagnosed Prevalent Cases of MS
Figure 7: 7MM, Sources Used and Not Used to Forecast the Diagnosed Prevalent Cases of MS by Type
Figure 8: 7MM, Diagnosed Incident Cases of MS, N, Both Sexes, All Ages, 2018
Figure 9: 7MM, Age-Specific Diagnosed Incident Cases of MS, N, Both Sexes, All Ages, 2018
Figure 10: 7MM, Sex-Specific Diagnosed Incident Cases of MS, N, All Ages, 2018
Figure 11: 7MM, Diagnosed Prevalent Cases of MS, N, Both Sexes, All Ages, 2018
Figure 12: 7MM, Age-Specific Diagnosed Prevalent Cases of MS, N, Both Sexes, All Ages, 2018
Figure 13: 7MM, Sex-Specific Diagnosed Prevalent Cases of MS, N, All Ages, 2018
Figure 14: 7MM, Diagnosed Prevalent Cases of MS by Type, N, Both Sexes, All Ages, 2018